Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| BPC-157 (Oral Stable Form) | Sermorelin | |
|---|---|---|
| Category | Peptides | Peptides |
| Standard Dose | Research indicates 250-500 mcg twice daily via oral capsule on empty stomach. | Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection. |
| Timing | On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels. | Bedtime administration (aligns with natural nocturnal GH release). On empty stomach. |
| Cycle Duration | 4-12 weeks. Oral form enables easier long-term use compared to injectable. | 12-24 week cycles. Some protocols use continuous treatment. |
| Evidence Level | animal_plus_anecdotal | strong_human |
Oral-stable BPC-157, typically formulated as the arginate salt, retains the same mechanism as standard BPC-157 — promoting angiogenesis via VEGFR2/PI3K/Akt/eNOS and Src-Caveolin-1-eNOS pathways, enhancing nitric oxide production, and stimulating tendon fibroblast growth and collagen formation. The arginate salt provides a protective buffer against gastric acid degradation, maintaining peptide integrity across a wider pH range. BPC-157 demonstrates remarkable native stability in human gastric juice (24+ hours), and the arginate form reportedly achieves 7-fold greater oral bioavailability compared to the acetate salt in preclinical studies.
Research indicates 250-500 mcg twice daily via oral capsule on empty stomach.
On empty stomach, 30 minutes before meals. Twice daily dosing (morning and evening) provides consistent levels.
4-12 weeks. Oral form enables easier long-term use compared to injectable.
Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.
Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
12-24 week cycles. Some protocols use continuous treatment.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →